This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Hims & Hers Health (HIMS) and Nurix Therapeutics (NRIX)

Tipranks - Tipranks - Wed Jun 10, 6:36AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD), Hims & Hers Health (HIMS) and Nurix Therapeutics (NRIX).

Introducing TipRanks MCP for Agents

Gilead Sciences (GILD)

In a report released yesterday, Carter Gould from Cantor Fitzgerald maintained a Buy rating on Gilead Sciences, with a price target of $155.00. The company’s shares closed last Monday at $128.10.

According to TipRanks.com, Gould is a 4-star analyst with an average return of 5.4% and a 50.8% success rate. Gould covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Eli Lilly & Co. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $160.11, representing a 23.1% upside. In a report issued on May 26, Scotiabank also maintained a Buy rating on the stock with a $177.00 price target.

See the top stocks recommended by analysts >>

Hims & Hers Health (HIMS)

In a report released today, Jailendra Singh from Truist Financial reiterated a Hold rating on Hims & Hers Health. The company’s shares closed last Monday at $27.17.

According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -11.0% and a 37.6% success rate. Singh covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Hinge Health, Inc. Class A, and Fortrea Holdings Inc. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hims & Hers Health with a $27.41 average price target, representing a 3.5% upside. In a report issued on May 28, Bank of America Securities also maintained a Hold rating on the stock with a $25.00 price target.

Nurix Therapeutics (NRIX)

J.P. Morgan analyst Tessa Romero maintained a Buy rating on Nurix Therapeutics yesterday. The company’s shares closed last Monday at $15.64.

According to TipRanks.com, Romero is a 4-star analyst with an average return of 14.1% and a 48.9% success rate. Romero covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., EyePoint Pharmaceuticals, and Rocket Pharmaceuticals. ;'>

Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.00, which is a 97.3% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $45.00 price target.

Read More on GILD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).